GlobeStar Therapeutics Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James C. Katzaroff
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 719 Jadewin Avenue Richland WA United States of America 99352
- IPO Date
- Sep 26, 2011
- CIK
- 0001502152
- Website
- globestartherapeutics.com
- Similar Companies
- Business
- GlobeStar Therapeutics Corporation (GSTC) is a clinical-stage biotechnology and pharmaceutical company focused on developing patented formulations of previously FDA-approved drugs for treating neurodegenerative diseases, particularly multiple sclerosis (MS) and peripheral artery disease (PAD). The company offers Project Amethyst, a proprietary therapeutic compound comprising a custom cocktail of minocycline, fluconazole, and atorvastatin aimed at addressing MS-related neurodegeneration; it holds exclusive worldwide licensing rights to all related patents, including U.S. Patent #10610592, with preclinical data from an Italian study of 150 participants showing significant improvements in disability scores, balance, motor control, and bladder function after 45 days of treatment. Founded in 2016 and headquartered at 719 Jadwin Avenue in Richland, Washington, with additional operations noted in New York, New York, GlobeStar targets patients with chronic neurological conditions through clinical trials, regulatory submissions, manufacturing, and global distribution. In late 2023, GlobeStar entered a definitive agreement with SMI Healthcare LLC to manage initial clinical trials, regulatory filings, intellectual property, manufacturing, sales, and distribution for Project Amethyst in regions including Southeast Asia, Africa, and the East; it also formalized a collaboration with Advanced Innovative Partners (AIP) for strategic advisory on global clinical trial design, regulatory processes, and implementation, building on a prior 2023 memorandum of understanding. The company, formerly known as AngioSoma, Inc., rebranded to GlobeStar Therapeutics Corporation in July 2021 to reflect its expanded biotechnology platform.
Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials
GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment
Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis
GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign
GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season